EOLS — Evolus, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1570562 ·
Last close
$6.69
Market Cap
$442.80M
52W High
$9.31
52W Low
$3.86
ADV30
974,315
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 77,952,000 | 50,686,000 | -5,782,000 | -12,516,000 | 283,823,000 | 41,700,000 | 321,637,000 |
| Jun 2026 | 84,084,000 | 57,180,000 | -3,293,000 | -8,052,000 | 248,024,000 | 45,170,000 | 278,927,000 |
| Mar 2026 | 73,137,000 | 48,897,000 | -6,862,000 | -10,674,000 | 220,646,000 | 49,792,000 | 249,427,000 |
| Dec 2025 | 90,300,000 | 59,291,000 | -291,000 | 130,000 | 225,868,000 | 53,826,000 | 248,974,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-2,645,000
Investing CF
$-6,171,000
Financing CF
$7,432,000
CapEx
$-6,171,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.47
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-692,282,000
Inventory
$82,804,000
Receivables
$60,280,000
ST Investments
—
EBIT TTM
$-13,968,000
Pretax Income TTM
$-30,340,000
Interest Exp TTM
$16,372,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$325,472,992
EBITDA
$-8,275,000
Free Cash Flow
$13,406,625
Enterprise Value
$573,982,080
Total Cash
$41,700,000
Total Debt
$165,584,992
Shares Out
66,188,366
Trailing EPS
$-0.48
Book Value
$-0.57
ROE
—
ROA
-4.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 297,176,000 | -37,600,000 | -51,641,000 | 225,868,000 | 248,974,000 | -23,106,000 | -42,265,000 |
| Dec 2024 | 266,274,000 | -27,235,000 | -50,420,000 | 232,569,000 | 227,047,000 | 5,522,000 | -17,999,000 |
| Dec 2023 | 202,085,000 | -44,976,000 | -61,685,000 | 188,998,000 | 209,687,000 | -20,689,000 | -34,008,000 |
| Dec 2022 | 148,616,000 | -59,575,000 | -74,412,000 | 177,983,000 | 159,484,000 | 18,499,000 | -84,912,000 |
TTM Snapshot
Revenues TTM
$316,488,000
NetIncome TTM
$-34,333,000
OpCashFlow TTM
—
Assets (Latest)
$248,024,000
Forward EPS
$0.29
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $7.07 · call volume: 33 · put volume: 13
Expected Move to 2027-01-15:
±$1.25
(17.68%) —
implied range
$5.82 –
$8.32
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INDP | Indaptus Therapeutics, Inc. | $442.36M | $3.32 | — |
| ARVN | ARVINAS, INC. | $446.61M | $6.82 | — |
| PHAT | Phathom Pharmaceuticals, Inc. | $447.10M | $5.50 | — |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $437.41M | $6.62 | — |
| DMAC | DiaMedica Therapeutics Inc. | $452.16M | $8.38 | — |
News headlines (Yahoo Finance, 1h cache)
Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows
2026-11-16 02:12 · Yahoo
Evolus (EOLS) Q3 2026 Earnings Call Transcript
2026-11-05 16:28 · Yahoo
Evolus, Inc. Q3 2026 Earnings Call Summary
2026-11-05 13:30 · Yahoo
Evolus Inc (EOLS) (Q3 2026) Earnings Call Highlights: Fourth Consecutive Positive Adjusted ...
2026-11-05 13:09 · Yahoo
What Evolus (EOLS) Said on Its Q3 Earnings Call
2026-11-05 02:14 · Yahoo
Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates
2026-11-04 23:45 · Yahoo
Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlo
2026-11-04 21:05 · Yahoo
Evolus to Participate in Upcoming Investor Conferences in New York and London
2026-10-28 12:30 · Yahoo
Evolus to Report Third Quarter Financial Results on November 4, 2026
2026-10-21 12:30 · Yahoo
Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
2026-10-14 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.